Subscribe To Our Free Newsletter |
Glenmark Pharma settles Paragraph IV litigation with Forest Laboratories
The pharma company has entered into a Settlement Agreement with Forest Laboratories Forest Laboratories Holdings and Royalty Pharma Collection Trust to settle and dismiss the outstanding patent litigation related to Glenmark’s Abbreviated New Drug Application for Milnacipran Hydrochloride.